A Bridging Study on the Bioequivalence of Fluzoparib Capsules With Different Specifications in Healthy Volunteers
Latest Information Update: 17 Aug 2021
At a glance
- Drugs Fuzuloparib (Primary)
- Indications Breast cancer; Fallopian tube cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 10 Aug 2021 Results published in the British Journal of Clinical Pharmacology
- 26 Aug 2020 New trial record